Abbott Laboratories announced Thursday that it will pay $670 million to resolve claims brought by approximately 2,000 individuals alleging that its specialty infant formulas for preterm infants caused necrotizing enterocolitis (NEC), a severe bowel disease with a mortality risk exceeding 20 percent. The deal was struck with three plaintiff law firms and encompasses the case behind the $495 million St. Louis jury verdict from 2024 — a verdict a Missouri appellate court affirmed in May 2026 and that is currently on appeal to the Missouri Supreme Court. The settlement does not resolve the broader litigation: close to 1,000 comparable lawsuits remain pending against Abbott and Mead Johnson, including more than 800 consolidated in an Illinois federal court, plus state court claims in Illinois, Missouri, and Pennsylvania. For plaintiff firms, this is the first aggregate resolution in the NEC litigation, and it establishes an implied per-claim benchmark — roughly $335,000 gross on average across the settled inventory — that every remaining negotiation will now orbit.
What Abbott agreed to
Precision matters here, because early coverage has blurred the scope. Based on what has been reported, this is a private aggregate settlement between Abbott and three plaintiff law firms, resolving the claims of roughly 2,000 people. It is not a global class resolution, not a court-approved settlement program covering the consolidated federal docket, and not — so far as the reporting shows — an agreement that binds Mead Johnson, the manufacturer of Enfamil, in any respect.
Three features of the deal are confirmed by the reporting:
- The headline number: $670 million in the aggregate to resolve approximately 2,000 claims alleging harm from Abbott's specialty preterm formulas.
- The verdict inside the deal: the settlement encompasses the case in which a St. Louis jury ordered Abbott to pay $495 million in 2024 after finding the company's formula responsible for an Illinois girl's NEC. Abbott's appeal of that verdict is pending before the Missouri Supreme Court after a state court of appeals affirmed in May 2026.
- What remains outside: nearly 1,000 comparable lawsuits against Abbott and Mead Johnson, with more than 800 consolidated in Illinois federal court and additional claims in Illinois, Missouri, and Pennsylvania state courts.
Several material terms are not yet public. Abbott has not officially named the three settling firms, though two of the three can be established by inference — see the section below. Nor has Abbott disclosed the allocation methodology — whether the deal uses an injury-severity matrix, walk-away thresholds requiring minimum participation, or lien-resolution machinery. Nor is it known how the settlement formally disposes of the pending Missouri Supreme Court appeal: whether the appeal will be dismissed, and on what timeline. Firms tracking this litigation should treat those as open items rather than assume standard structures.
One arithmetic point deserves attention: the reporting counts roughly 1,000 filed suits against both defendants combined, while this settlement resolves claims from 2,000 people. Read together, those figures suggest a substantial share of the settled claims were unfiled inventory held by the three firms — a familiar pattern in mass resolutions, and one that has direct implications for how the remaining filed docket is valued.
Which law firms settled with Abbott?
Abbott has not named the three firms — the company's press release and SEC Form 8-K say only that it reached agreements with three law firms. Two of the three, however, can be established by inference: the settlement resolves the Gill case, and Gill v. Abbott Laboratories (No. 2322-CC01251, 22nd Judicial Circuit Court of Missouri, St. Louis) was tried by TorHoerman Law, with Jake Plattenberger as lead trial counsel, and Stranch, Jennings & Garvey PLLC, with Hon. John (Jack) Garvey as co-lead counsel. A resolution of the Gill judgment necessarily runs through the Gill family's counsel, and both firms hold substantial NEC claim inventories beyond the verdict case itself. The identity of the third settling firm has not been reported as of this update. One firm can be ruled out: Keller Postman, which leads the parallel state-court track — including the April 2026 $70 million Cook County verdict against Abbott and the 2024 $60 million Watson verdict against Mead Johnson — is not among the settling firms. The public record points the same direction: Abbott's Form 8-K describes the deal as resolving the Gill case and roughly 2,000 additional claims, with no mention of the Cook County verdict, which would be a required disclosure if that exposure were being resolved. Keller Postman's inventory of thousands of state-court claims remains live — which matters for the next phase, because the firm most likely to keep trying cases against Abbott just declined to exit. The third settling firm's likely profile is an inventory-holding firm rather than a trial firm, since the roughly 2,000 additional claims — a number well in excess of the filed docket — represent the balance of the deal. This article will be updated when the third firm is confirmed.
How this litigation got here
The NEC formula litigation targets Abbott (maker of Similac products) and Mead Johnson (maker of Enfamil) over cow's-milk-based formulas and fortifiers given to premature infants, principally in hospital NICU settings. Plaintiffs allege the companies failed to warn that these products elevate the risk of necrotizing enterocolitis, a condition in which bowel tissue dies. The disease primarily strikes premature infants and, per the reporting on this settlement, carries a mortality risk above 20 percent. Bloomberg characterized the underlying allegation as claims that Abbott hid the risk its preterm formula "can cause a deadly bowel disease."
The defense position has been consistent throughout: both companies maintain that breast milk is protective against NEC but that their formulas do not cause the disease. That causation dispute has been the central battleground of the litigation and will remain so for every claim not resolved by this deal.
The procedural architecture is split across forums. More than 800 cases are consolidated in an Illinois federal court, with parallel state court tracks in Illinois, Missouri, and Pennsylvania. Missouri state court has been the litigation's most consequential venue to date: it produced the 2024 St. Louis verdict of $495 million against Abbott — the result that, more than any other single event, established trial risk in this tort. Abbott appealed, lost at the intermediate appellate level in May 2026, and took the case to the Missouri Supreme Court. Roughly three months after that affirmance, Abbott settled — and folded the verdict into the deal.
That sequence is the story. Abbott litigated the flagship case through verdict and one full round of appeal, and only after the affirmance narrowed its realistic paths to reversal did it move to a large aggregate resolution. Whatever Abbott says publicly about causation, its litigation behavior now reflects a priced-in assessment of trial and appellate risk.
What it changes
A valuation benchmark now exists. Until Thursday, the NEC litigation had verdict data points but no aggregate settlement data. $670 million across roughly 2,000 claims implies a gross average in the neighborhood of $335,000 per claim — before fees, costs, liens, and before accounting for the near-certainty that allocations vary widely by injury severity (death cases versus surgical NEC versus medical-management cases). That average is also distorted by the inclusion of a $495 million affirmed verdict inside the pool; how the settling firms allocate around that case is unknown. Abbott's own Form 8-K sharpens the picture: the company described its alternative as paying approximately $600 million for the Gill judgment plus accrued interest. If the Gill allocation sits anywhere near that exposure, the incremental cost of the entire 2,000-claim inventory could be as low as roughly $70 million — on the order of $35,000 per claim — though the Gill family presumably accepted some discount to settle, which places the true inventory average somewhere between that floor and the blended $335,000 figure. Firms should treat the blended average as a negotiating anchor, not a per-case expectation. Counsel negotiating on behalf of unsettled claimants will nonetheless treat the implied average as a floor for argument purposes — and Abbott will argue the opposite, that this was a discount purchase of a concentrated inventory including its worst appellate exposure.
The 800+ MDL cases are untouched — and arguably strengthened. Nothing in the reporting indicates this deal alters the federal consolidated proceeding's schedule, discovery posture, or bellwether program. What it does alter is leverage. Abbott has now demonstrated a willingness to pay nine figures to resolve NEC inventories at scale. Firms holding federal and state court cases outside the three settling firms have every incentive to press forward toward trial settings rather than accept early, discounted offers. Whether the federal court responds with renewed bellwether scheduling — and whether Abbott seeks a pause to pursue further inventory deals — are the key procedural questions of the next quarter. The reporting does not yet answer them.
Mead Johnson's calculus just got harder. Mead Johnson is not reported to be part of this settlement, and roughly half the litigation narrative — the Enfamil side — remains fully live. But co-defendants rarely benefit when one defendant establishes a settlement market. Every mediator, every state court judge, and every plaintiff negotiating committee now has an Abbott comparable to point to. If Mead Johnson continues to try cases on its breast-milk-is-protective causation defense, it does so knowing its co-defendant concluded that defense was not worth betting the appellate courts on.
The appeal question is the sleeper issue. Abbott settled while its Missouri Supreme Court appeal of the $495 million verdict was still pending. The reporting does not disclose whether the settlement moots, dismisses, or conditions anything on that appeal. The distinction matters beyond this deal: a Missouri Supreme Court merits ruling — in either direction — would have been precedent shaping every future Missouri NEC trial. If the settlement takes the case off the court's docket, the intermediate appellate affirmance from May 2026 stands as the operative Missouri authority, which is a favorable posture for plaintiffs in that venue and an unfavorable one for Mead Johnson, which loses the chance that Abbott's appeal would generate helpful law.
What this means for plaintiff firms
Expect an awareness spike, and expect it to be broad. A $670 million settlement number attached to infant formula generates mainstream coverage in a way that procedural rulings never do. Historically in this litigation, the big awareness drivers have been verdicts; this is the first settlement-driven wave, and settlement headlines convert differently — they signal to potential claimant families that compensation is real and being paid, not merely litigated. Firms running NEC campaigns should anticipate elevated search and inquiry volume in the near term, with the usual caveat that headline-driven inquiries skew toward marginal fact patterns and require disciplined screening on prematurity, NICU formula exposure, and confirmed NEC diagnosis.
The demand-side window is competitive and time-limited. Three firms just exited with 2,000 claims resolved. The firms holding the remaining filed inventory — and those building new inventory — are now competing for a claimant population that is inherently finite: NEC is a rare condition affecting a narrow cohort of premature infants. When a resolution event of this size hits a finite-population tort, acquisition competition typically intensifies quickly and media costs move with it. Firms weighing whether to enter or scale NEC intake should be making that decision now, against current per-tort market data, rather than after competitors have absorbed the awareness spike.
Case valuation discipline matters more, not less. The implied per-claim average will circulate widely, and referral and co-counsel conversations will start anchoring to it. Firms should resist quoting it loosely: it blends an affirmed nine-figure verdict with what appears to be a large unfiled inventory, and severity-tiered allocations mean individual outcomes will diverge sharply from the average. For co-counsel and referral economics, the more defensible framing is that Abbott has established it will pay for well-documented NEC cases at scale — which raises the value of rigorously worked-up files and lowers tolerance for thin ones.
Watch the Mead Johnson side for the second wave. If Abbott's resolution pressures Enfamil-side settlement talks, firms with mixed Similac/Enfamil inventories are positioned for two resolution events rather than one. Nothing in the current reporting indicates Mead Johnson negotiations, so treat that as a scenario, not a fact.
Open questions
- Which firm is the third settling firm alongside Gill trial counsel TorHoerman Law and Stranch, Jennings & Garvey, and what allocation structure and participation thresholds does the deal impose?
- Does the settlement formally dismiss the Missouri Supreme Court appeal of the $495 million verdict, leaving the May 2026 affirmance as standing Missouri authority?
- Will the Illinois federal court respond with renewed bellwether scheduling for the 800+ consolidated cases, and will Abbott pursue additional inventory deals before any federal trial?
- Does Mead Johnson open settlement discussions on the Enfamil side, or continue trying cases on its causation defense?
- How much of the settled 2,000-claim pool was unfiled inventory, and what does that imply about the remaining filed docket's composition?
Sources
- Abbott Laboratories — Form 8-K Exhibit 99.1, August 20, 2026 (SEC EDGAR)
- Abbott — Press Release: Agreements to Resolve a Portion of Preterm Formula Litigation, August 20, 2026
- Bloomberg — Abbott Will Pay $670 Million to End 2,000 Infant Formula Claims
- Devdiscourse — Abbott's $670 Million Settlement Resolves Infant Formula Legal Claims
Mass Tort Ad Agency is a plaintiff-side advertising agency, not a law firm. Nothing in this article is legal advice.